| Name | Title | Contact Details |
|---|
MedAmerica is one of the leading healthcare practice management organizations in the United States. Since 1975, we have successfully managed hospital-based physician group practices across the Acute Care Continuum, with expertise in emergency medicine, hospital medicine, ambulatory & urgent care, and other acute care specialties. We provide the strategy, solutions, and systems to help our clients successfully navigate today’s complex healthcare landscape. MedAmerica offers a full range of cost-effective practice management solutions. We’re in the business of enabling physician groups, hospitals, and other healthcare organizations to be more efficient, productive, and profitable – all while providing higher quality care and improved outcomes.
We`re Villa Healthcare, and we make people better. Of course, we`re focused on quality care and good outcomes. But we`re here to do so much more. At Villa, we offer the very best in post-acute and long-term care. Our focus is providing exceptional clinical services by people who truly care, in an environment that promotes healing and wellness. Villa`s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We`ve always wanted to be a part of something greater, and we`ve made that a reality by both making people better and by creating and sharing opportunities. We currently have 22 facilities in four different states*. As Villa has grown, we have redoubled our efforts to ensure that the Villa experience is the same at every location. By extensively renovating our centers and hiring the best people we can, we are making our mark in the world of healthcare. It`s how Villa makes people better.
Medigraphics Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FOREO is a Swedish multi-national beauty brand established and headquartered Stockholm, Sweden.
Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.